Insights

Portfolio expansion Piramal Critical Care (PCC) through Minrad-like entities is actively expanding its injectable portfolio with launches and acquisitions, signaling opportunities to cross-sell complementary generic injectables and establish co-marketing or distribution partnerships in critical care settings.

EU UK growth Recent news indicates PCC acquiring commercialization rights for Neoatricon in EU, UK, Norway and SA, presenting a route to expand market access and identify regional procurement opportunities, tenders, and hospital channels to target with compatible products.

Critical care focus Company concentrates on critical care injectables such as Edaravone, Pantoprazole, Doxycycline, and Zinc Sulfate, suggesting a sales opportunity to offer compatible sterile manufacturing, fill/finish or packaging services, plus regulatory and quality support to streamline launches.

Digital commerce Tech stack includes cloud platforms, CRM and analytics tools (iCIMS, Qlik, AWS, Azure, Google Cloud, SharePoint, Jira, LinkedIn tags), indicating readiness for data-driven selling, digital marketing, and partner onboarding solutions to accelerate outreach and account-based campaigns.

Strategic leadership momentum Executive appointment of a President/COO in 2023 and focus on asset commercialization signal strategic growth and potential collaborations with contract manufacturers, distributors, and service providers to support scale in manufacturing, logistics, and global distribution.

Similar companies to Minrad

Minrad Tech Stack

Minrad uses 8 technology products and services including Linkedin Insight Tag, iCIMS, Qlik, and more. Explore Minrad's tech stack below.

Media & News

Minrad's Email Address Formats

Minrad uses at least 1 email format:
Minrad Email FormatsExamplePercentage
FLast@minrad.comJDoe@minrad.com
100%

Frequently Asked Questions

What is Minrad's official website and social media links?

Minus sign iconPlus sign icon
Minrad's official website is piramalcriticalcare.com and has social profiles on LinkedIn.

How much revenue does Minrad generate?

Minus sign iconPlus sign icon
As of July 2026, Minrad's annual revenue is estimated to be $50M - $100M.

What is Minrad's NAICS code?

Minus sign iconPlus sign icon
Minrad's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Minrad have currently?

Minus sign iconPlus sign icon
As of July 2026, Minrad has approximately 51 employees across 3 continents, including North America, Europe and Oceania. Key team members include Safety Manager: W. A. Explore Minrad's employee directory with LeadIQ.

What industry does Minrad belong to?

Minus sign iconPlus sign icon
Minrad operates in the Medical Devices industry.

What technology does Minrad use?

Minus sign iconPlus sign icon
Minrad's tech stack includes Linkedin Insight Tag, iCIMS, Qlik, Amazon Web Services, Microsoft SharePoint, Google Cloud Platform, Atlassian Jira and Microsoft Azure.

What is Minrad's email format?

Minus sign iconPlus sign icon
Minrad's email format typically follows the pattern of FLast@minrad.com. Find more Minrad email formats with LeadIQ.
Minrad logo

Minrad

Medical DevicesUnited States51-200 Employees

Minrad operates in the medical equipment manufacturing sector in the United States, with a focus on providing injectable and critical care products through its parent brand, Piramal Critical Care. The company’s portfolio includes a range of injectable medications used in acute and intensive care settings, expanding its offerings through periods of product launches to broaden the scope of generic injectables available in the U.S. market. Its customer base comprises healthcare providers and facilities that require ready-to-use intravenous therapies for critical care, with product introductions aimed at enhancing treatment options in hospital environments. Based in the United States and part of Piramal Pharma’s critical care division, Minrad situates itself within the broader life sciences equipment and pharmaceutical supply chain, contributing to the availability of essential injectable medications. A notable recent development involves the launch of Edaravone IV Infusion and other injectables, reflecting ongoing portfolio expansion in the critical care space. Although specific market metrics are not disclosed, the company operates with a size indicative of a mid-sized organization within the medical equipment manufacturing landscape.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Employees
51-200

Section iconFunding & Financials

  • $50M - $100M

    Minrad's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.